BNP and echocardiographic parameters in patients with chronic kidney disease and dialyzed patients

Czech version

Authors: I. Valočiková ¹; G. Valočik ²; B. Krištofová ¹; Ľ. Družbacká ²; R. Roland ³; P. Mitro ²
Authors‘ workplace: I. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednostka prof. MU Dr. Ivica Lazúrová, CSc. ¹; III. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta doc. MU Dr. Peter Mitro, Ph. D. ²; FRESENIUS, Nefrologické a dialyzačné centrum Košice, Slovenská republika, prednosta prim. MU Dr. Robert Roland ³
Published in: Vnitř Lék 2009; 55(10): 934-939
Category: Original Contributions

Overview

We assessed the relation between BNP levels and some echocardiographic parameters of systolic and diastolic function of the left ventricle in 49 patients (mean age 69.39 ± 8.47 years) with chronic kidney disease in different stages of chronic renal failure according to K/ DOQI and in 45 subjects (mean age 52.6 ± 14.85 years) on dialysis. Median for BNP in the group of patients with chronic renal failure was 132 pg/ ml, and in dialysis subjects 320 pg/ ml. None of our patients had clinical signs of heart failure during the last six months. Using a method of correlation matrix we found the left ventricular mass and its indexed value as a common indicator of increased BNP level in both groups of patients (dialysis patients, p = 0.0003, and p = 0.0005, respectively; patients with chronic renal failure, p = 0.03, and p = 0.04, respectively). Further analysis proved that in the group of dialysis patients the main determinants of increased BNP level were volumes of the left heart side: left ventricular enddiastolic volume (p = 0.004), endsystolic volume (p = 0.01), and left atrial volumes (maximal, minimal, and total atrial stroke volume; p = 0.004, p = 0.009 a p = 0.04, respectively). In the group of patients with chronic renal failure the major contributors to increased BNP level were echocardiographic parameters of diastolic filling assessed from transmitral and pulmonary venous flow: E wave (p = 0.001), A wave (p = 0.01), E/ A (p < 0.001), IVRT (p = 0.004), E/ EDT (p < 0.0001), S wave (p = 0.01), D wave (p = 0.0003), S/ D (p = 0.001), Ar duration (p = 0.02), and E/ Vp (p = 0.003). No significant relation to left ventricular ejection fraction was found in both groups of patients. Our results suggest that the main determinant of increased BNP level in patients with different stages of chronic renal failure is diastolic dysfunction, whereas in dialysis patients high left heart volumes due to volume overload. The common denominator of high BNP level in both groups of patients is especially the left ventricular mass.

Key words:
chronic renal disease – chronic renal failure – systolic and diastolic dysfunction – cardiac biomarkers – BNP

Sources

1. Joffy L, Rosner MH. Natriuretic peptides in ESRD. Am J Kidney Dis 2005; 46: 1– 10.

2. Roberts MA, Hare DL, Ratnaike S et al. Cardiovascular Biomarkers in CKD: Pathophysiology and Implication for Clinical Management of Cardiac Disease. Am J Kidney Dis 2006; 48: 341– 360.

3. Totsune K, Takahashi K, Satoh F et al. Urinary immunoreactive brain natriuretic peptide in patients with renal disease. Regul Pept 1996; 63: 141– 147.

4. Vasavada N, Agarwal R. Role of excess volume in the pathopsysiology of hypertension in chronic kidney disease. Kidney Int 2003; 64: 1772– 1779.

5. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296– 1305.

6. Shlipak MG, Heidenreich PA, Noguchi H et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555– 562.

7. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285– 1295.

8. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2000; 13: 1918– 1927.

9. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613– 618.

10. Herzog CA. Dismal long‑term survival of dialysis patients after acute myocardial infarction: can we alter the outcome? Nephrol Dial Transplant 2002; 17: 7– 10.

11. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in haemodialysis patients: an evidence‑based review. Hemodial Int 2007; 11: 1– 14.

12. Logar CM, Herzog CA, Beddhu S. Diagnosis and therapy of coronary artery disease in renal failure, end‑stage renal disease, and renal transplant population. Am J Med Sci 2003; 325: 214– 227.

13. Garg AX, Clark WF, Haynes RB et al. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 2002; 61: 1486– 1494.

14. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow‑up and outcomes among a population with chronic kidney disease in a large managed care organisation. Arch Intern Med 2004; 164: 659– 663.

15. Sarnak MJ, Coronado BE, Greene T et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327– 335.

16. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527– 1539.

17. Cameron SJ, Green GB. Cardiac biomarkers in renal disease: the fog is slowly lifting. Clinical Chem 2004; 50: 2233– 2235.

18. Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens 2005; 14: 532– 537.

19. Mallamaci F, Tripepi G, Cutrupi S et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330– 2337.

20. Cazzovillan S, Ratanarat R, Segala C et al. Inflammation and subclinical infection in chronic kidney disease: a molecular approach. Blood Purif 2007; 25: 69– 76.

21. Agarwal S, Dangri P, Kalra OP et al. Echocardiographic assessment of cardiac dysfunction in patients of chronic renal failure. JIAM 2003; 4: 296– 303.

22. de Almeida EA, de Oliveira EI, Lopés JA et al. Diastolic function in several stages of chronic kidney disease in patients with autosomal dominant polycystic kidney disease: a tissue doppler imaging study. Kidney Blood Press Res 2007; 30: 234– 239.

23. Miyazato J, Horio T, Takiuchi S et al. Left ventricular diastolic dysfuction in patients with chronic renal failure: impact of diabetes mellitus. Diabet Med 2005; 22: 730– 736.

24. Hayashi SY, Rohani M, Lindholm B. Left ventricular function in patients with chronic kidney disaese evaluated by colour tissue Doppler velocity imaging. Nephrol Dial Transplant 2006; 21: 125– 132.

25. Wanic- Kossowska M, Lehmann P, Czekalski S. Left ventricular systolic and diastolic dysfunction in patients with chronic renal failure treated with hemodialysis. Pol Arch Med Wewn 2003; 109: 365– 373.

26. Ludka O, Špinar J, Vítovcová L et al. Význam stanovení NT- proBNP a big endotelinu pro diagnostiku chronického srdečního selhání u nemocných v pravidelném hemodialyzačním programu. Vniř Lék 2007; 53: 38– 45.

27. Ludka O, Špinar J, Vítovcová L et al. Variabilita plazmatických hladin big endotelinu a NT- proBNP u nemocných se srdečním selháním v chronickém hemodialyzačním programu. Vniř Lék 2007; 53: 1177– 1181.

28. Berger AK, Duval S, Krumholz HM. Aspirin, beta‑blocker and angiotensin‑converting enzyme inhibitor therapy in patients with end‑stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42: 201– 208.

29. French WJ, Wright RS. Renal insufficiency and worsened prognosis with STEMI: a call for action. J Am Coll Cardiol 2003; 42: 1544– 1546.